Akari Therapeutics Analyst Price Targets - Benzinga

Akari Therapeutics PLC

AKTXNASDAQ

Trade with Public

Trade with Public

$11.47

0.635.81%

가까이에: Sep 4, 5:00 PM EST

$12.95

1.4812.9%

시간외: Sep 4, 5:51 PM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Akari Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Akari Therapeutics (AKTX).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$19Upside to Avg. PT+49.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 20, 2026	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$30
Apr 8, 2026	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Apr 1, 2026	HC Wainwright & Co.	Sean Lee	PT Raise	Buy	$2→$27
Jan 5, 2026	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$1
Sep 9, 2025	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$2
Jul 18, 2025	Maxim Group	Jason McCarthy	Initiate	Buy	$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Akari Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades Akari Therapeutics (NASDAQ:AKTX) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Akari Therapeutics, Maintains $1.6 Price Target

HC Wainwright & Co. analyst Sean Lee reiterates Akari Therapeutics (NASDAQ:AKTX) with a Buy and maintains $1.6 price target.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $5

Maxim Group analyst Jason McCarthy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $5.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022

Benzinga Insights

PRO
HC Wainwright & Co. Initiates Coverage On Akari Therapeutics with Buy Rating, Announces Price Target of $1.5

HC Wainwright & Co. analyst Sean Lee initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $1.5.

Benzinga Newsdesk